Clinical Trials - Completed

The clinical trials listed in this section have ended and are no longer treating patients - all recruitment and follow-up has completed. Often the results will affect clinical practice, future treatment of patients and may lead to new clinical trials or further research. Members can review the Trial Report in the Members Area.

Filter AGITG trials by

A randomised trial of preoperative radiotherapy for stage T3 adenocarcinoma of rectum. Read More

A randomised phase III multicentre study evaluating the role of palliative surgical resection of the primary tumour in patients with metastatic colorectal cancer. Read More

A Multicentre Phase II study of Risk Evaluation in GIST with Slecetive Therapy Escalation for Response. Read More

Multi-centre International Study of capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer. Read More

A randomised phase II study evaluating potential predictive biomarkers in the treatment of locally advanced and metastatic pancreatic cancer. Read More

A randomised placebo controlled study of OSI-774 (Tarceva) plus gemcitabine in patients with locally advanced, unresectable or metastatic pancreatic cancer. Read More

A randomised phase II/III study to evaluate the role of Mitomycin C, Avastin and Xeloda in patients with untreated metastatic colorectal cancer. Read More

A Randomised, Controlled Trial of Pre- and Post- Operative Chemotherapy in Patients with Operable Gastric and Lower Oesophageal Cancer. Read More

A randomised multicentre phase III study in patients with locally advanced adenocarcinoma of the pancreas; gemcitabine with or without chemoradiotherapy and with or without erlotinib. Read More

A Randomised Phase II Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Oesophago-Gastric Cancer (AOGC). Read More

Individualised Molecular Pancreatic Cancer Therapy Read More

Phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5-FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. Read More

Phase III adjuvant trial in pancreatic cancer comparing: 5- fluorouracil + D-L folinic acid with gemcitabine or no adjuvant treatment. Read More

Pre and post-operative chemotherapy with oxaliplatin 5-FU/LV versus surgery alone in resectable liver metastases from colorectal origin - phase III study. Read More

A randomised phase II trial of weekly docetaxel (Taxotere®) chemoradiotherapy +/- cetuximab (Erbitux®) in the treatment of localised resectable cancer of the oesophagus. Read More

Randomised phase II trial of De Gramont schedule 5- fluorouracil and leucovorin plus irinotecan versus single agent irinotecan in patients with previously treated metastatic colorectal cancer. Read More

A Phase III Randomised Study of Brivanib Alaninate (BMS- 582664) in Combination with Cetuximab (ERBITUX®) Versus Placebo in Combination with Cetuximab (ERBITUX®) in Patients With K-Ras Wild Type Tumours Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma. Read More

A phase III randomised study of cetuximab (ERBITUXTM, C225) and best supportive care versus best supportive care in patients with pre-treated metastatic epidermal growth factor receptor (EGFR) positive colorectal carcinoma. Read More

A clinical trial comparing 5-fluorouracil (5-FU) plus leucovorin (LV) and oxaliplatin with 5-FU plus LV for the treatment of patients with stages II and III carcinoma of the colon. Read More

A clinical trial comparing oral uracil/ftorfur (UFT) plus leucovorin (LV) with 5-fluorouracil (5-FU) plus LV in the treatment of stages II and III carcinoma of the colon. Read More

ABC

Biliary tract cancers are uncommon; as a result it is not a well-studied disease and treatment options for this condition are limited. This study will assess the impact of a new combination of chemotherapy drugs on the growth of the cancer and the undesirable side-effects of treatment. Read More

This study will help to decide which treatments are most promising and should be compared with current treatments in the future in an effort to improve the time people live after a diagnosis of oesophageal or gastric cancer. Read More

A randomised phase II study evaluating weekly docetaxel, cisplatin, fluoropyrimidine (wTCF) plus or minus panitumumab in advanced oesophago-gastric cancer. Read More

Phase II study of cetuximab (Erbitux™) plus weekly docetaxel chemotherapy in docetaxel refractory patients with EGFR positive advanced oesophago-gastric cancer. Read More

A Trial in the Timing of Surgery and Adjuvant Chemotherapy for Hepatic Metastases from ColorEctal Cancer. Read More

Phase II pilot study of Sandostatin LAR ® in the treatment of advanced hepatocellular carcinoma. Read More

A phase II study of irinotecan, leucovorin and 5- fluorouracil in advanced gastric cancer. Read More

A phase II feasibility study of pre-operative and post- operative chemotherapy using epirubicin, cisplatin and protracted venous infusion fluorouracil (ECF) in patients with advanced but operable gastric cancer. Read More

A randomised trial of early chemotherapy in asymptomatic metastatic colorectal cancer. Read More

A phase III randomised study of BB1608 and best supportive care versus placebo and best supportive care in patients with pretreated advanced colorectal carcinoma. Read More

The SCOT trial has helped researchers answer an important health question about bowel cancer treatment. Its results may change the way some bowel cancers are treated in the future. Read More

The ADVANCED GIST/AG0102 GIST/EORTC 62005 trial compares the outcome of patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing KIT (CD117) treated with low dose imatinib versus high dose imatinib. Read More

The TACTIC study aims to evaluate the safety and efficacy of combining panitumumab with standard cisplatin and gemcitabine chemotherapy for advanced biliary tract cancer. Read More

PETACC-6 aims to investigate if using a combination of capecitabine with oxaliplatin as chemotherapy in the pre- and post-operative treatment setting reduces the risk of recurrence or death in patients with locally advanced rectal cancer. Read More

The ICECREAM study aims to provide important data on the optimal use of currently available therapeutics in patients with metastatic colorectal cancer who have progressed on standard chemotherapy options. The trial is designed to answer two questions in parallel. Read More

GAP

The primary objective of the GAP trial is to determine the effect of pre-operative chemotherapy in patients with pancreatic cancer. Read More

The Adjuvant GIST study (also known as EORTC 62024) investigated Imatinib in people with resectable GISTs. Read More